Clinical trialNCT00267358CompletedPhase 2Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

SponsorHelsinn Therapeutics (U.S.), IncCancer Cachexia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

William Polvino, MD
Helsinn Therapeutics (U.S.), Inc
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Palo Verde Hematology Oncology Ltd.
Glendale, Arizona, United States
Comprehensive Blood & Cancer Center
Bakersfield, California, United States
Pacific Oncology & Hematology Associates
Encinitas, California, United States
Pacific Oncology and Hematology Associates
Encinitas, California, United States
Advanced Medical Research Institute
Fresno, California, United States
Kenmar Clinical Research
Los Angeles, California, United States
Kenmar Research Institute
Los Angeles, California, United States
Sant Chawla, Inc.
Santa Monica, California, United States
Pab Clinical Research
Brandon, Florida, United States
Melbourne Internal Medicine Associates
Melbourne, Florida, United States
Osler Medical, Inc./ Osler Clinical Research
Melbourne, Florida, United States
Bay Area Oncology
Tampa, Florida, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Hematology Oncology Consultants, Inc.
Columbus, Ohio, United States
Charleston Cancer Center
Charleston, South Carolina, United States
South Carolina Oncology Associates
Columbia, South Carolina, United States
South Carolina Cancer Specialists
Hilton Head Island, South Carolina, United States
University of Texas Medical Texas
Galveston, Texas, United States
Multicare Health System
Tacoma, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboRC-1291 HCl

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2005
Primary completion: 31 Oct 2006
Completion: 31 Oct 2006
Last update posted: 2 Sept 2013
Registered enrollment: —
Registry id: NCT00267358

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.